Moderna

US · MRNA #406 by market cap Listed 2018

196.48 +9.02 +4.81%

Live - 5344 symbols - heartbeat 4s ago · 2026-10-08 07:00

Pre-market 194.65 -0.93%

After-hours 195.47 -0.51%

Overnight 195.45 -0.52%

Market cap: 78.44B
P/E (TTM): -24.62
P/B: 11.60
EPS: -7.26
Div yield: 0.00%
52W pos: 92%

Reader sentiment Are you bullish or bearish on MRNA?

Anonymous reader poll. Unscientific, not investment advice.

About Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Founded: 2010
CEO: Mr. Stephane Bancel
Employees: 4,700
Headquarters: Cambridge, Massachusetts, United States of America
Fiscal year end: 12-31
Website: modernatx.com

Company profile

Exchange: US
Symbol: MRNA
Market-cap rank: #406
Listing date: 2018-12-07
Market cap: 78.44B
Float cap: 73.14B
Shares out: 399.24M
Float shares: 372.26M

Sectors & themes

Biotechnology Infectious Disease Regular Savings Plan Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:11 · For reference only, not investment advice and not tailored to your situation.